Is VKORC1 useful for menopause?

Based on current evidence, VKORC1 is not useful for managing menopause. VKORC1 encodes the vitamin K epoxide reductase complex, which influences vitamin K-dependent proteins like osteocalcin (bone health) and matrix Gla protein (vascular calcification). In theory, genetic variants could affect bone density or cardiovascular risk during menopause, but no direct clinical studies support using VKORC1 testing for menopause-related decisions. The primary clinical application of VKORC1 genotyping is warfarin dosing, not menopause. Evidence is limited to mechanistic plausibility and extrapolation from pharmacogenetics. Without prospective trials or guidelines, consumer tests claiming relevance for menopause are premature. Women should rely on established assessments (e.g., DXA scans, lipid profiles, symptom tracking) rather than unproven genetic markers. The evidence level is 'unclear' due to lack of human studies specifically addressing menopause outcomes.